{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:53:21Z","timestamp":1794030801978,"version":"4.8.0"},"reference-count":43,"publisher":"American Association for Cancer Research (AACR)","issue":"4","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tempest Therapeutics","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>TPST-1120 is a first-in-class oral inhibitor of peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1), a fatty acid ligand-activated transcription factor that regulates genes involved in fatty acid oxidation, angiogenesis, and inflammation, and is a novel target for cancer therapy. TPST-1120 displayed antitumor activity in xenograft models and synergistic tumor reduction in syngeneic tumor models when combined with anti-PD-1 agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>This phase I, open-label, dose-escalation study (NCT03829436) evaluated TPST-1120 as monotherapy in patients with advanced solid tumors and in combination with nivolumab in patients with renal cell carcinoma (RCC), cholangiocarcinoma (CCA), or hepatocellular carcinoma. Objectives included evaluation of safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity (RECIST v1.1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 39 patients enrolled with 38 treated (20 monotherapy, 18 combination; median 3 prior lines of therapy). The most common treatment-related adverse events (TRAE) were grade 1\u20132 nausea, fatigue, and diarrhea. No grade 4\u20135 TRAEs or dose-limiting toxicities were reported. In the monotherapy group, 53% (10\/19) of evaluable patients had a best objective response of stable disease. In the combination group, 3 patients had partial responses, for an objective response rate of 20% (3\/15) across all doses and 30% (3\/10) at TPST-1120 \u2265400 mg twice daily. Responses occurred in 2 patients with RCC, both of whom had previously progressed on anti-PD-1 therapy, and 1 patient with late-line CCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>TPST-1120 was well tolerated as monotherapy and in combination with nivolumab and the combination showed preliminary evidence of clinical activity in PD-1 inhibitor refractory and immune compromised cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>TPST-1120 is a first-in-class oral inhibitor of PPAR\u03b1, whose roles in metabolic and immune regulation are implicated in tumor proliferation\/survival and inhibition of anticancer immunity. This first-in-human study of TPST-1120 alone and in combination with nivolumab supports proof-of-concept of PPAR\u03b1 inhibition as a target of therapeutic intervention in solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0082","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T09:32:42Z","timestamp":1711704762000},"page":"1100-1110","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPAR\u03b1, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-0748","authenticated-orcid":true,"given":"Mark","family":"Yarchoan","sequence":"first","affiliation":[{"name":"1Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7608-0380","authenticated-orcid":true,"given":"John D.","family":"Powderly","sequence":"additional","affiliation":[{"name":"2Carolina BioOncology Institute, Huntersville, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0577-4358","authenticated-orcid":true,"given":"Bruno R.","family":"Bastos","sequence":"additional","affiliation":[{"name":"3Baptist Health Miami Cancer Institute, Miami, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-5392","authenticated-orcid":true,"given":"Thomas B.","family":"Karasic","sequence":"additional","affiliation":[{"name":"4Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8602-8309","authenticated-orcid":true,"given":"Oxana V.","family":"Crysler","sequence":"additional","affiliation":[{"name":"5University of Michigan Rogel Cancer Center, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2074-0984","authenticated-orcid":true,"given":"Pamela N.","family":"Munster","sequence":"additional","affiliation":[{"name":"6UCSF Health \u2013 UCSF Medical Center, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0944-7418","authenticated-orcid":true,"given":"Meredith A.","family":"McKean","sequence":"additional","affiliation":[{"name":"7Sarah Cannon Research Institute, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7694-0731","authenticated-orcid":true,"given":"Leisha A.","family":"Emens","sequence":"additional","affiliation":[{"name":"8UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7074-2681","authenticated-orcid":true,"given":"Yvonne M.","family":"Saenger","sequence":"additional","affiliation":[{"name":"9Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6671-7002","authenticated-orcid":true,"given":"Yasser","family":"Ged","sequence":"additional","affiliation":[{"name":"1Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3797-0151","authenticated-orcid":true,"given":"Robert","family":"Stagg","sequence":"additional","affiliation":[{"name":"10Tempest Therapeutics, Brisbane, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6593-1406","authenticated-orcid":true,"given":"Steven","family":"Smith","sequence":"additional","affiliation":[{"name":"10Tempest Therapeutics, Brisbane, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2040-4227","authenticated-orcid":true,"given":"Chan C.","family":"Whiting","sequence":"additional","affiliation":[{"name":"10Tempest Therapeutics, Brisbane, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6710-8993","authenticated-orcid":true,"given":"Anne","family":"Moon","sequence":"additional","affiliation":[{"name":"10Tempest Therapeutics, Brisbane, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6637-4551","authenticated-orcid":true,"given":"Peppi","family":"Prasit","sequence":"additional","affiliation":[{"name":"10Tempest Therapeutics, Brisbane, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1917-9248","authenticated-orcid":true,"given":"Yonchu","family":"Jenkins","sequence":"additional","affiliation":[{"name":"10Tempest Therapeutics, Brisbane, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9328-1889","authenticated-orcid":true,"given":"Nathan","family":"Standifer","sequence":"additional","affiliation":[{"name":"10Tempest Therapeutics, Brisbane, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0726-4597","authenticated-orcid":true,"given":"Thomas W.","family":"Dubensky","sequence":"additional","affiliation":[{"name":"10Tempest Therapeutics, Brisbane, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8736-0583","authenticated-orcid":true,"given":"Sam H.","family":"Whiting","sequence":"additional","affiliation":[{"name":"10Tempest Therapeutics, Brisbane, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7234-2283","authenticated-orcid":true,"given":"Susanna V.","family":"Ulahannan","sequence":"additional","affiliation":[{"name":"11Stephenson Cancer Center of the University of Oklahoma\/Sarah Cannon Research Institute, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"2024041814011821400_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2024041814011821400_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrc3483","article-title":"Cancer metabolism: fatty acid oxidation in the limelight","volume":"13","author":"Carracedo","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"2024041814011821400_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.canlet.2018.08.006","article-title":"Fatty acid oxidation: an emerging facet of metabolic transformation in cancer","volume":"435","author":"Ma","year":"2018","journal-title":"Cancer Lett"},{"key":"2024041814011821400_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br J Cancer"},{"key":"2024041814011821400_bib5","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","article-title":"Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets","volume":"186","author":"Michalek","year":"2011","journal-title":"J Immunol"},{"key":"2024041814011821400_bib6","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ni.2956","article-title":"Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages","volume":"15","author":"Huang","year":"2014","journal-title":"Nat Immunol"},{"key":"2024041814011821400_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cmet.2006.05.011","article-title":"Oxidative metabolism and PGC-1\u03b2 attenuate macrophage-mediated inflammation","volume":"4","author":"Vats","year":"2006","journal-title":"Cell Metab"},{"key":"2024041814011821400_bib8","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1172\/JCI62129","article-title":"A metabolic prosurvival role for PML in breast cancer","volume":"122","author":"Carracedo","year":"2012","journal-title":"J Clin Investig"},{"key":"2024041814011821400_bib9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr Rev"},{"key":"2024041814011821400_bib10","doi-asserted-by":"crossref","first-page":"7726","DOI":"10.1111\/febs.16181","article-title":"PPAR\u03b1 at the crossroad of metabolic\u2013immune regulation in cancer","volume":"289","author":"Zeng","year":"2022","journal-title":"FEBS J"},{"key":"2024041814011821400_bib11","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1186\/1471-2164-15-1106","article-title":"Transcriptomic signatures of peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) in different mouse liver models identify novel aspects of its biology","volume":"15","author":"Szalowska","year":"2014","journal-title":"BMC Genomics"},{"key":"2024041814011821400_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.tem.2012.05.001","article-title":"PPARs at the crossroads of lipid signaling and inflammation","volume":"23","author":"Wahli","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"2024041814011821400_bib13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"2024041814011821400_bib14","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1371\/journal.pone.0000260","article-title":"PPAR\u03b1 deficiency in inflammatory cells suppresses tumor growth","volume":"2","author":"Kaipainen","year":"2007","journal-title":"PLoS One"},{"key":"2024041814011821400_bib15","article-title":"US Patent No.676,754 B2. Triazolone compounds and uses thereof","author":"Stock","year":"2017"},{"key":"2024041814011821400_bib16","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1158\/1538-7445.AM2019-3606","article-title":"Blockade of the PPAR\u03b1 metabolic checkpoint with TPST-1120 suppresses tumor growth and stimulates anti-tumor immunity [abstract]","volume":"79","author":"Whiting","year":"2019","journal-title":"Cancer Res"},{"key":"2024041814011821400_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"2024041814011821400_bib18","doi-asserted-by":"crossref","first-page":"100235","DOI":"10.1016\/j.xpro.2020.100235","article-title":"Profiling of mouse macrophage lipidome using direct infusion shotgun mass spectrometry","volume":"2","author":"Hsieh","year":"2021","journal-title":"STAR Protoc"},{"key":"2024041814011821400_bib19","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1021\/jasms.1c00203","article-title":"A DMS shotgun lipidomics workflow application to facilitate high-throughput, comprehensive lipidomics","volume":"32","author":"Su","year":"2021","journal-title":"J Am Soc Mass Spectrom"},{"key":"2024041814011821400_bib20","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/hmg\/ddab372","article-title":"Systematic identification of genomic elements that regulate FCGR2A expression and harbor variants linked with autoimmune disease","volume":"31","author":"Dahlqvist","year":"2021","journal-title":"Hum Mol Genet"},{"key":"2024041814011821400_bib21","doi-asserted-by":"crossref","first-page":"29120","DOI":"10.1074\/jbc.272.46.29120","article-title":"CCAAT-Enhancer-binding Proteins (C\/EBP) regulate the tissue specific activity of the CD11c integrin gene promoter through functional interactions with Sp1 proteins*","volume":"272","author":"L\u00f3pez-Rodr\u0131\u0301guez","year":"1997","journal-title":"J Biol Chem"},{"key":"2024041814011821400_bib22","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.165.6.3190","article-title":"Synergistic induction of the tap-1 gene by IFN-\u03b3 and lipopolysaccharide in macrophages is regulated by STAT1","volume":"165","author":"Cramer","year":"2000","journal-title":"J Immunol"},{"key":"2024041814011821400_bib23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1084\/jem.181.4.1459","article-title":"Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter","volume":"181","author":"Wright","year":"1995","journal-title":"J Exp Med"},{"key":"2024041814011821400_bib24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.neo.2018.03.004","article-title":"The STAT3 target gene TNFRSF1A modulates the NF-\u03baB pathway in breast cancer cells","volume":"20","author":"Egusquiaguirre","year":"2018","journal-title":"Neoplasia"},{"key":"2024041814011821400_bib25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3389\/fimmu.2019.00464","article-title":"The human Fc\u03b3RII (CD32) family of leukocyte FcR in health and disease","volume":"10","author":"Anania","year":"2019","journal-title":"Front Immunol"},{"key":"2024041814011821400_bib26","doi-asserted-by":"crossref","first-page":"110111","DOI":"10.1016\/j.celrep.2021.110111","article-title":"Inflammatory macrophages exploit unconventional pro-phagocytic integrins for phagocytosis and anti-tumor immunity","volume":"37","author":"Tang","year":"2021","journal-title":"Cell Rep"},{"key":"2024041814011821400_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fcell.2019.00091","article-title":"TNFR1 and TNFR2 in the control of the life and death balance of macrophages","volume":"7","author":"Wajant","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"2024041814011821400_bib28","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"2024041814011821400_bib29","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024041814011821400_bib30","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med"},{"key":"2024041814011821400_bib31","doi-asserted-by":"crossref","first-page":"e152670","DOI":"10.1172\/JCI152670","article-title":"Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers","volume":"131","author":"Yarchoan","year":"2021","journal-title":"J Clin Invest"},{"key":"2024041814011821400_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"2024041814011821400_bib33","doi-asserted-by":"crossref","first-page":"3449660","DOI":"10.1155\/2022\/3449660","article-title":"REchallenge of NIVOlumab (RENIVO) or nivolumab-ipilimumab in metastatic renal cell carcinoma: an ambispective multicenter study","volume":"2022","author":"Vauchier","year":"2022","journal-title":"J Oncol"},{"key":"2024041814011821400_bib34","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/jamaoncol.2020.2169","article-title":"Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma","volume":"6","author":"Ravi","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024041814011821400_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.yexcr.2018.12.005","article-title":"PPAR\u03b1 suppresses Th17 cell differentiation through IL-6\/STAT3\/ROR\u03b3t pathway in experimental autoimmune myocarditis","volume":"375","author":"Chang","year":"2019","journal-title":"Exp Cell Res"},{"key":"2024041814011821400_bib36","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s42003-023-05104-6","article-title":"Ppar\u03b1 knockout in mice increases the Th17 development by facilitating the IKK\u03b1\/ROR\u03b3t and IKK\u03b1\/Foxp3 complexes","volume":"6","author":"Wei","year":"2023","journal-title":"Commun Biol"},{"key":"2024041814011821400_bib37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.21037\/hbsn-20-688","article-title":"Myeloid peroxisome proliferator-activated receptor \u03b1 deficiency accelerates liver regeneration via IL-6\/STAT3 pathway after 2\/3 partial hepatectomy in mice","volume":"11","author":"Xie","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2024041814011821400_bib38","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.4049\/jimmunol.1500449","article-title":"Antagonizing peroxisome proliferator\u2013activated receptor \u03b1 activity selectively enhances Th1 immunity in male mice","volume":"195","author":"Zhang","year":"2015","journal-title":"J Immunol"},{"key":"2024041814011821400_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/384039a0","article-title":"The PPAR\u03b1\u2013leukotriene B4 pathway to inflammation control","volume":"384","author":"Devchand","year":"1996","journal-title":"Nature"},{"key":"2024041814011821400_bib40","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1189\/jlb.0605341","article-title":"The role of the peroxisome proliferator-activated receptor-\u03b1 (PPAR-\u03b1) in the regulation of acute inflammation","volume":"79","author":"Cuzzocrea","year":"2006","journal-title":"J Leukoc Biol"},{"key":"2024041814011821400_bib41","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1517\/14728222.2012.715633","article-title":"PPAR\u03b1 as a therapeutic target in inflammation-associated diseases","volume":"16","author":"Gervois","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"2024041814011821400_bib42","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/hep.27297","article-title":"The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice","volume":"60","author":"Pawlak","year":"2014","journal-title":"Hepatology"},{"key":"2024041814011821400_bib43","unstructured":"Tempest Therapeutics Inc. Tempest releases new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in randomized first-line HCC study; 2023. Available from: https:\/\/ir.tempesttx.com\/news-releases\/news-release-details\/tempest-releases-new-data-demonstrating-superiority-tpst-1120."}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0082\/3435505\/crc-24-0082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/4\/1100\/3442866\/crc-24-0082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/4\/1100\/3442866\/crc-24-0082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T10:01:56Z","timestamp":1713434516000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/4\/1100\/743074\/First-in-human-Phase-I-Trial-of-TPST-1120-an"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,18]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0082","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.25639221.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639257.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639230.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639248.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639260","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639230","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639242","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639254","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639245.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639224","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639236","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639248","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639242.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639239.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639236.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639233.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639227.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639251.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639254.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639224.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639260.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639251","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639221","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639233","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639245","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639257","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639227","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25639239","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7189296","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7189296.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}